NCT00237120View on ClinicalTrials.gov

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

June 30, 2007

Conditions
Chronic Myelogenous Leukemia in Chronic Phase
Interventions
DRUG

Imatinib

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY